Alkermes plc Reports First Quarter 2023 Financial Results
Alkermes plc (Nasdaq: ALKS) reported first-quarter 2023 revenues of $287.6 million, a 3.9% increase from $278.5 million in Q1 2022. The growth is attributed to a remarkable 25% surge in net sales of proprietary products, totaling $214.7 million. Notably, LYBALVI's sales jumped 173% to $38 million, while VIVITROL and ARISTADA saw increases of 14% and 10%, respectively. Despite these positives, the company reported a GAAP loss per share of $0.25 compared to $0.22 the previous year. Alkermes reiterated its financial expectations for 2023 and is on track for the planned separation of its oncology business in H2 2023. Additionally, Alkermes received a favorable arbitration ruling regarding royalties, amounting to $194 million.
- First-quarter revenues of $287.6 million, a 3.9% increase year-over-year.
- Net sales of proprietary products rose by 25% to $214.7 million.
- LYBALVI sales increased by 173% to $38 million.
- Favorable arbitration ruling resulting in approximately $194 million in back royalties.
- GAAP loss per share widened to $0.25 from $0.22 in the prior year.
- Operating expenses increased to $335.1 million, a rise from $305.1 million.
— First Quarter Revenues of
— GAAP Loss per Share of
— Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 —
— Second Favorable Interim Award Received in Janssen Arbitration —
— Financial Expectations for 2023 Reiterated —
DUBLIN, April 26, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023.
"During the first quarter we made continued progress across our portfolio, including strong commercial execution driving growth for our proprietary products – LYBALVI®, VIVITROL® and ARISTADA® – and important progress in the development of ALKS 2680, our orexin 2 receptor agonist, which is now poised to enter a phase 1b proof-of-concept study in patients with narcolepsy and idiopathic hypersomnia, with data expected later this year," said Richard Pops, Chief Executive Officer of Alkermes. "In addition, we made significant operational and strategic advances in the planned separation of our oncology business, which remains on track for completion in the second half of this year. We remain sharply focused on executing our strategic priorities to create significant value for shareholders."
"Our strong first quarter financial results were driven by
Quarter Ended March 31, 2023 Financial Results
Revenues
- Total revenues for the quarter were
- Net sales of proprietary products for the quarter increased approximately
- Net sales of VIVITROL were
$96.7 million , compared to$84.9 million for the same period in the prior year, representing an increase of approximately14% . - Net sales of ARISTADAi were
$80.1 million , compared to$72.5 million for the same period in the prior year, representing an increase of approximately10% . - Net sales of LYBALVI were
$38.0 million , compared to$13.9 million for the same period in the prior year, representing an increase of approximately173% .
- Manufacturing and royalty revenues for the quarter were
- Royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® (the long-acting INVEGA products) for the quarter were
$13.6 million , compared to$37.1 million for the same period in the prior year. This decrease was driven primarily by Janssen Pharmaceutica N.V.'s (Janssen), a subsidiary of Johnson & Johnson, partial termination of the license agreement related to sales of the long-acting INVEGA products in the United States (U.S.), effective Feb. 2, 2022. - Manufacturing and royalty revenues from VUMERITY® for the quarter were
$28.9 million , compared to$30.6 million for the same period in the prior year.
Costs and Expenses
- Total operating expenses for the quarter were
- Cost of Goods Manufactured and Sold was
$58.2 million , compared to$55.2 million for the same period in the prior year. - Research and Development (R&D) expenses were
$93.6 million , compared to$96.0 million for the same period in the prior year. - Selling, General and Administrative (SG&A) expenses were
$174.5 million , compared to$145.1 million for the same period in the prior year, primarily reflecting increased investment to support the launch of LYBALVI.
Profitability
- Net loss according to generally accepted accounting principles in the U.S. (GAAP) was
- Non-GAAP net income was
Balance Sheet
- At March 31, 2023, the company recorded cash, cash equivalents and total investments of
Financial Expectations for 2023
Alkermes reiterates its financial expectations for 2023, as set forth in its press release dated Feb. 16, 2023.
Separation of Oncology Business
Alkermes continues to make meaningful progress on the previously announced planned separation of the company's oncology business. The separation would allow Alkermes to maintain its focus on researching, developing and commercializing therapies for people living with complex neurological conditions and is expected to accelerate and enhance the profitability of the remaining neuroscience business.
- As previously announced, in April, Alkermes submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission (SEC) in connection with the planned separation of its oncology business into an independent, publicly-traded company. Upon completion of the planned separation, the new company would be known as Mural Oncology plc.
- Alkermes continues to expect to complete the separation in the second half of 2023, subject to various customary conditions, including final approval from Alkermes' board of directors.
Recent Events
Corporate
- In April 2023, the company received a second favorable interim award (the Second Interim Award) from the arbitral tribunal (the Tribunal) in the company's arbitration proceedings with Janssen in respect of Janssen's partial termination in the U.S. of two license agreements with the company. The Second Interim Award, which builds on the first interim award that was issued in December 2022, provides that back royalties related to 2022 of approximately
Neuroscience
- In February 2023, the company initiated a multiple ascending dose cohort in the phase 1 study of its ALKS 2680 orexin 2 receptor agonist, which is in clinical development for the treatment of narcolepsy and other hypersomnia conditions.
- In March 2023, the company announced the publication of results from its phase 3 ENLIGHTEN-Early study of LYBALVI in the peer-reviewed publication, the Journal of Clinical Psychiatry. ENLIGHTEN-Early evaluated the effect of LYBALVI compared to olanzapine on body weight in young adult patients (ages 16 to 39; mean age: 26 years) with schizophrenia, schizophreniform disorder or bipolar I disorder who were early in their illness.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 26, 2023, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted (loss) earnings per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net (loss) income adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; change in the fair value of contingent consideration; certain other one-time or non-cash items; and the income tax effect of these reconciling items.
The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP financial measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net (loss) income and non-GAAP basic and diluted (loss) earnings per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net (loss) income and non-GAAP basic and diluted (loss) earnings per share should not be considered measures of the company's liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including its ability to execute on its strategic priorities and create value for shareholders; the company's expectations regarding the royalties and interest due to the company and royalty terms under the license agreements with Janssen; the company's expectations regarding the timing, structure, anticipated benefits and other impacts of the planned separation of the oncology business; timelines, plans and expectations for development activities relating to ALKS 2680; and the therapeutic and commercial potential of the company's products. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not ultimately separate its oncology business during 2023 or at all; unanticipated developments, costs or difficulties that may delay or otherwise negatively affect a potential separation of the company's neuroscience and oncology businesses; disruption to the company's operations resulting from the planned separation; the planned separation may adversely impact the company's ability to attract or retain key personnel; the terms of the final award to be issued by the Tribunal may differ from the terms of the interim awards issued by the Tribunal and may be challenged by Janssen; the unfavorable outcome of arbitration or litigation, including so-called "Paragraph IV" litigation and other patent litigation which may lead to competition from generic drug manufacturers, or other disputes related to the company's products or products using the company's proprietary technologies; the impacts of the ongoing COVID-19 pandemic on the company's business, results of operations or financial condition, including impacts on healthcare systems and on patient and healthcare provider access to the company's marketed products; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company's regulatory approval strategies or components of the company's marketing applications; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K and in subsequent filings made by the company with the SEC, which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; BYANNLI®, INVEGA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.
(tables follow)
______________________________________ |
i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise. |
Alkermes plc and Subsidiaries | ||||
Selected Financial Information (Unaudited) | ||||
Condensed Consolidated Statements of Operations - GAAP | Three Months Ended | Three Months Ended | ||
(In thousands, except per share data) | March 31, 2023 | March 31, 2022 | ||
Revenues: | ||||
Product sales, net | $ 214,727 | $ 171,268 | ||
Manufacturing and royalty revenues | 72,862 | 105,170 | ||
License revenue | — | 2,000 | ||
Research and development revenue | 6 | 107 | ||
Total Revenues | 287,595 | 278,545 | ||
Expenses: | ||||
Cost of goods manufactured and sold | 58,175 | 55,159 | ||
Research and development | 93,637 | 95,953 | ||
Selling, general and administrative | 174,477 | 145,052 | ||
Amortization of acquired intangible assets | 8,800 | 8,966 | ||
Total Expenses | 335,089 | 305,130 | ||
Operating Loss | (47,494) | (26,585) | ||
Other Expense, net: | ||||
Interest income | 4,966 | 573 | ||
Interest expense | (5,288) | (2,350) | ||
Change in the fair value of contingent consideration | — | (19,067) | ||
Other (expense) income, net | (39) | 2,431 | ||
Total Other Expense, net | (361) | (18,413) | ||
Loss Before Income Taxes | (47,855) | (44,998) | ||
Income tax benefit | (6,010) | (9,095) | ||
Net Loss — GAAP | $ (41,845) | $ (35,903) | ||
(Loss) Earnings Per Share: | ||||
GAAP loss per share — basic and diluted | $ (0.25) | $ (0.22) | ||
Non-GAAP earnings per share — basic and diluted | $ 0.01 | $ 0.12 | ||
Weighted Average Number of Ordinary Shares Outstanding: | ||||
Basic — GAAP and Non-GAAP | 165,085 | 162,483 | ||
Diluted — GAAP | 165,085 | 162,483 | ||
Diluted — Non-GAAP | 170,270 | 166,616 | ||
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows: | ||||
Net Loss — GAAP | $ (41,845) | $ (35,903) | ||
Adjustments: | ||||
Share-based compensation expense | 22,643 | 18,343 | ||
Depreciation expense | 9,914 | 10,231 | ||
Amortization expense | 8,800 | 8,966 | ||
Separation expense | 3,783 | — | ||
Income tax effect related to reconciling items | (995) | (1,193) | ||
Non-cash net interest expense | 116 | 117 | ||
Change in the fair value of contingent consideration and other related assets | — | 19,067 | ||
Non-GAAP Net Income | $ 2,416 | $ 19,628 | ||
Alkermes plc and Subsidiaries | ||||
Selected Financial Information (Unaudited) | ||||
Condensed Consolidated Balance Sheets | March 31 | December 31, | ||
(In thousands) | 2023 | 2022 | ||
Cash, cash equivalents and total investments | $ 692,542 | $ 740,075 | ||
Receivables | 269,178 | 287,967 | ||
Inventory | 184,984 | 181,418 | ||
Contract assets | 8,429 | 8,929 | ||
Prepaid expenses and other current assets | 47,008 | 43,527 | ||
Property, plant and equipment, net | 321,109 | 325,361 | ||
Intangible assets, net and goodwill | 121,753 | 130,553 | ||
Deferred tax assets | 151,232 | 115,602 | ||
Other assets | 126,492 | 130,546 | ||
Total Assets | $ 1,922,727 | $ 1,963,978 | ||
Accounts payable and accrued expenses | $ 472,413 | $ 472,204 | ||
Long-term debt — current portion | 3,000 | 3,000 | ||
Other current liabilities | 17,497 | 22,538 | ||
Long-term debt | 289,635 | 290,270 | ||
Other long-term liabilities | 134,606 | 132,213 | ||
Total shareholders' equity | 1,005,576 | 1,043,753 | ||
Total Liabilities and Shareholders' Equity | $ 1,922,727 | $ 1,963,978 | ||
Ordinary shares outstanding (in thousands) | 166,059 | 164,377 | ||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in | ||||
Alkermes Contacts: | ||
For Investors: | Sandy Coombs | +1 781 609 6377 |
For Media: | Katie Joyce | +1 781 249 8927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-plc-reports-first-quarter-2023-financial-results-301807602.html
SOURCE Alkermes plc
FAQ
What were Alkermes' Q1 2023 earnings?
How did Alkermes' revenues perform in Q1 2023?
What growth did Alkermes see in its proprietary products?
What is the status of the planned separation of Alkermes' oncology business?
